

Ikonisys Group Secures Major Public Contract for Ikoniscope20 Robotic Microscope in Italy

Paris, November 25, 2024 - 6:00 p.m. CET - Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the achievement of a significant milestone in its commercial journey through its wholly owned subsidiary, Hospitex. Just eight months after its integration into the Group, Hospitex has been awarded another prestigious public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in Caserta, Italy.

The public tender, valued at €123k, involves the purchase of the Ikoniscope20, a compact version of the world's most advanced U.S.-manufactured FISH (Fluorescence In Situ Hybridization) microscope. This milestone marks a breakthrough for Ikonisys Group as it secures its first major foothold in the public sector.

This success closely follows the recent strategic agreement with SYNLAB Italia¹ for the supply of FISH instruments and reagents. These achievements highlight the Ikonisys Group's ability to perform effectively in both public and private markets, showcasing the robustness of its commercial strategy.

"This tender win not only highlights the technological excellence of the Ikoniscope20 but also validates our growth strategy," stated **Francesco Trisolini, COO of Ikonisys Group**. *"Entering the public market is a significant step forward, paving the way for future opportunities in both sectors."*

The combined successes in public and private markets position the Ikonisys Group for further growth, setting the stage for additional tenders in 2025. With cutting-edge solutions and a clear strategy, Ikonisys Group is on track to strengthen its leadership in the microscopy and diagnostics sectors.

About Hospitex

Hospitex is part of the Ikonisys Group, a global leader in advanced diagnostic solutions. Leveraging cutting-edge robotic technologies, the company focuses on delivering innovative and precise solutions for laboratories and hospitals worldwide. More specifically, Hospitex is a world leader in oncology diagnostics, renowned for its production of advanced diagnostic instruments and reagents at its state-of-the-art facility in Florence.

¹ ["Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories"](#), November 4, 2024

Contact

Hospitex

Marco Testini

Investor Relations

marco.testini@hospitex.com

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys-finance.com

Contacts

Ikonisys

Alessandro Mauri

CFO

investors@ikonisys.com

NewCap

Louis-Victor Delouvrier/Aurélie Manavarere

Investor Relations

ikonisys@newcap.eu

Tel.: +33 (0)1 44 71 94 94

NewCap

Nicolas Merigeau

Media Relations

ikonisys@newcap.eu

Tel.: +33 (0)1 44 71 94 98

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.